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Abstract 
The woodchuck hepatitis B virus (WHV), the closest genetically related virus of HBV, and its natural host Marmota monax
constitute a well recognized animal model. The application of this model for the evaluation of immunogenicity and protection of 
new formulations of HBV vaccines for human use, for lamivudine-CHO-PreS/S vaccine therapy and WHV particles coupled 
with HBV derived woodchuck PreS/S antibodies (IC complex) studies, as shown that the PreS/S-CHO vaccine is the first human 
vaccine able to elicit non sterilizing protection in the woodchuck model. The very early appearance and selection of the domain B 
FLLA motif resistant mutant not neutralized by the antibodies produced following vaccination, has confirmed that more potent 
antivirals and/or multiple targeted options with possible inclusion of immune complexes should be considered. 
© 2009 Elsevier B.V. 
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1. Introduction 
Hepatitis B virus (HBV) infection is a relevant health problem worldwide. Estimated infected person are more 
than 370 million. The availability of efficient antiviral treatment is needed to ameliorate the outcome and to limit the 
spread of infection. The applied vaccination programs have been shown to be able to induce lower infection rates 
and prevalence values in the different countries. However the currently applied recombinant HBsAg vaccine has to 
be administered in a three-dosage schedule. Furthermore low or absence of response may be observed in 
immunocompromised, older and obese individuals [1,2]. The possibility of emergence of viral escape mutants has 
also been shown, representing an additional biological limit [3]. The use of immunodominant epitopes combination, 
of new adjuvants and cytokines for new formulation vaccines represents a major challenge for prevention and for 
Procedia in Vaccinology 1 (2009) 35–40
Available online at www.sciencedirect.com
1877-282X © 2009 Published by Elsevier Ltd. 
doi:10.1016/j.provac.2009.07.007
New perspectives in vaccination and immunotherapies for HBV 
infections 
Emilio D’Ugo,a Claudio Argentini,a Stefania Catone,a Andrea Canitano,a Roberto 
Giuseppetti,a Reinhard Gluckb, Maria Rapicettaa*
aViral Hepatitis Unit, Department of Infectious, Parasitic and Immune-Mediated Disease, Istituto Superiore di Sanità, Rome 
bCrucell-Berna Biotech Ltd., Rehhagstrasse 79, CH-3018 Bern, Switzerland 
2nd Vaccine Global Congress, Boston 2008
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.
36  Emilio D’Ugo et al. / Procedia in Vaccinology 1 (2009) 35–40
potentiate and regulate immunotherapeutic strategies in HBV infections treatments [4]. For such preclinical studies, 
the woodchuck hepatitis virus (WHV) and its natural host, the Eastern woodchuck (Marmota monax), constitute a 
useful predictive model for the similarities in viral replication and pathogenesis with HBV [5]. Vaccine and 
immunotherapy studies have been recently performed from our group using this model. This paper reports the 
comparative results following the administration of HBV vaccines with different antigen and adjuvant compositions. 
Furthermore an immunotherapeutic approach, derived from HBsAg vaccination, was evaluated for antiviral activity 
in naturally infected WHV chronic carrier woodchucks. 
2. Animals and methods 
2.1. Woodchucks and sera 
The studies were conducted in adult woodchucks, trapped in the mid-Atlantic region of the United States and 
purchased from International Animal Exchange Inc. (Ferndale, MI). The animals received human care in 
compliance with the guidelines of the Italian Ministry of Health and were fed with aflatoxin-free laboratory rabbit 
chow until death. They were maintained in isolation in the animal facility at the Istituto Superiore di Sanità (the 
Italian National Institute of Health) in Rome. The blood samples containing ethylenediaminetetraacetic acid (EDTA) 
at a final concentration of 10 IU/ml were centrifuged at 1500 rpm for 10 min. Plasma was recovered and stored at 
−80°C. 
2.2. Vaccines, antivirals, Immunocomplex 
The used vaccines include CHO-HBsAg (preS1 and preS2 full sequences) without adjuvants and RC529 
adjuvanted virosomal S/Core proteins, were kindly provided by Berna Biotech of Bern, Switzerland. Lamivudine 
drug was provided by GlaxoWellcome Inc. The Immunocomplex (IC) was constituted by pooled sera derived from 
two CHO-PreS/S vaccinated woodchucks (anti-HBs titre 2.5 mIU) mixed with WHV (107 WHV-DNA copies) and 
incubated 1 h at 37°C. 
2.3. Serological assays 
Anti-HBs antibodies were detected using an immuno-assay ELISA AUSAB (Abbott Laboratories 100, Abbott 
Park Road, Abbott Park, Illinois). Serum antibodies to WHV core antigen (anti-WHc), antibodies to WHV “e” 
antigen (anti-WHe) and WHV “e” antigen (WHeAg) were detected using electro-chemo-luminescence immuno-
assays (Elecsys, Roche Molecular diagnostics) [6]. 
2.4. WHV-DNA quantification and sequencing 
WHV genome copies were determined using a TaqMan Real-Time PCR. Applied probes and primers and method 
were previously described [7]. The sensitivity of the Real-Time PCR was 50 copies per milliliter (copies/ml). 
Sequence analysis was carried out with ABI prism Dye terminator sequencing kit and ABI prism 7000 sequence 
detection system (Applied Biosystems). 
3. Results 
3.1. Immunogenicity of PreS/S and S/Core HBV vaccines and protection level after WHV challenge 
  
 The comparison between CHO derived PreS/S virosomal HBV and of RC529 adjuvanted S/Core vaccination is 
reported in Fig. 1. The kinetics of antibody response following the administration, of 4-5 injections of vaccines and 
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after the intravenous inoculation of challenge WHV (w197) in vaccinated woodchucks is shown. It could be 
observed that sustained anti-HBs response was present soon after the administration of the first dose for CHO-
PreS/S vaccine and after 2-4 injections for S/Core vaccine. Anti-HBs titres were higher after challenge, in the group 
of PreS/S vaccinated woodchucks in comparison with S/Core vaccinated, which, however, maintained sustained 
anti-Core response. 
Fig. 1. Kinetics of antibody response in vaccinated woodchucks. Arrows indicate intramuscular vaccine administrations (respectively 50 µg 
and 20 µg antigen content). Virus challenge (Ch) was performed with w197 inoculum containing 108g eq/dose. 
 Fig. 2 reports the viral and antibody markers, present in both groups, after WHV challenge. The anti-HBe 
response was observed earlier in S/Core vaccinated animals. It was also observed before the viral challenge. This 
could be explained by the presence of small amounts of truncated forms of Core antigen that were able to elicit 
anti-HBe response. In CHO-PreS/S vaccinated animals no signs of viral markers WHeAg and WHV-DNA were 
observed. In the contrast, in S/Core vaccinated woodchuck a lower protection level was present. HBeAg was 
detected in one out of three animal and WHV-DNA in all animal, however at titres up to up to 5 logs lower in 
respect to the control. 
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Fig. 2. WHV-DNA copies, WHeAg and antibody markers in vaccinated woodchucks after viral challenge.
3.2. Therapeutic studies: lamivudine/PreS/S vaccine and PreS/S Ab/WHV immunocomplex (IC) administration 
in WHV chronic carrier woodchucks 
  
 In Fig. 3 are reported the obtained results in terms of HBeAg and WHV-DNA in the animal groups treated with 
lamivudine/CHO-PreS/S vaccine (panel A) and immunocomplex (IC). In the panel A, two log decrease in titre of 
WHV-DNA was observed in the first 2 weeks of lamivudine/CHO-PreS/S vaccine. Early detection of resistant 
mutants FLLA motif A566T in B domain at week 2 was followed by the increase of viremia (see exemplified 
animal in Fig. 3). In the panel B is shown the level (copies/ml) of WHeAg and WHV-DNA in WHV chronic carrier 
woodchucks administered with an immunocomplex formed by viral particle and anti-PreS/S antibodies. The 
preliminary results clearly indicate the reduction of viral replication following the administration of the 
immunocomplex as shown by the 4-5 log WHV-DNA decrease in titre and seroconversion to anti WHe. 
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Fig. 3. Panel A. Lamivudine PreS/S vaccine administration in woodchuck w2988. WHV-DNA kinetics and humoral response (anti-HBs 
measurements). Top figure: lamivudine was orally administered dissolved in orange juice, at daily dose of 100 mg/kg body weight, for 40 weeks. 
Panel B. Immunogenic complex (IC) administration in WHV chronically infected woodchucks. IC was intravenously administered. Serum 
aliquot containing 2.5 mIU anti-HBs was mixed with equal aliquots of serum containing 107 WHV-DNA/50 µl incubated 1 h at 37°C before 
injection. 
4. Discussion 
The research efforts on HBV vaccines are particularly focused on the improvement of the immunogenicity 
properties to avoid the possible occurrence of low response and to shorten the injection schedule. This is of 
particular relevance for immunization campaigns in low developed countries. 
This paper reports the results of vaccination studies performed with the application of WHV/Marmota monax
preclinical model. The comparison of data from the application of different formulations of HBV vaccines for 
human use has shown the usefulness of the model for the evaluation of heterologous vaccines. Furthermore it was 
shown that the CHO-PreS/S vaccine was be able to induce, in comparison with the S/Core vaccine, more precocious 
and higher levels of anti-HBs. The application of the heterologous challenge constituted by the standardised w197 
inoculum [6] indicated the induction of various protection levels elicited by vaccines with different antigen 
compositions. 
 The improvement of post-vaccinal immune responses is of crucial importance for immuno-therapeutic 
applications. The administration, in therapeutic vaccinations of a vaccine based on yeast derived “S” protein alone, 
has failed to trigger antiviral status. Others immunomodulatory strategies are needed. Even if it has been shown that 
combinations therapy might be more beneficial and effective than the application of the antiviral nucleoside analogs 
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alone, in decreasing the level of viral replication, it has resulted, up to now, ineffective in eradicating the infection. 
The development of drug resistant mutants have also an important impact.  
 In a recent vaccine-therapeutic study from our group [7], in which lamivudine and PreS/S vaccine was applied, 
we have observed the rapid emergence of lamivudine resistant mutants that were not neutralised by the elicited post-
vaccinal antibodies. The failure of antiviral activity following the selection of B FLLA motif domain resistant and 
not neutralized viral mutants is an important finding that further support the need of more potent antivirals. 
Furthermore multiple targeted options should be considered. 
 Our recent preliminary experiment aimed at evaluating, in WHV naturally infected chronic carriers woodchucks, 
the antiviral activity of the immune complex (IC) composed by anti-PreS/S antibodies and WHV particles, showed a 
significant decrease (4-5 logs) in viral load in a part of administered woodchucks. These results are in accordance 
with the data of pilot studies in humans, in which immune complexes were administered in HBeAg positive patients 
leading to the decrease of HBV-DNA and HBeAg titres and to anti-HBe seroconversion [8]. The results are also in 
agreement with of other antiviral drug-immunomodulators combination studies performed in woodchucks [9]. 
 In conclusion, it was demonstrated that WHV/woodchuck model can be used for HBV vaccine studies, resulting 
the PreS/S-CHO vaccine the first human vaccine able to elicit non sterilizing protection in the woodchuck model. 
The level of the anti-HBs production seems to have a crucial role in neutralizing and protective immunity. The 
WHV/Marmota monax system could provide a well characterized model for preclinical evaluation of combined 
therapeutic approaches for prevention and treatment of HBV chronic disease. 
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